Screener
aTyr Pharma ATYR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of common stock through employee stock purchase plan | 16 | 79 |
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | — | 36,691 |
| Principal paid on finance lease liabilities | (287) | (264) |
| Net cash (used in) provided by financing activities | (271) | 36,525 |
| Net change in cash, cash equivalents and restricted cash | 4,677 | 6,092 |
| Cash, cash equivalents and restricted cash at beginning of period | 12,978 | 14,006 |
| Cash, cash equivalents and restricted cash at the end of period | $17,655 | $20,098 |
| Cash and cash equivalents at the end of period | $16,160 | $17,220 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's financing cash flow?
- aTyr Pharma (ATYR) reported financing cash flow of -$129K in Q2 2026.
- How has aTyr Pharma's financing cash flow changed year-over-year?
- aTyr Pharma's financing cash flow decreased by 100.7% year-over-year, from $17.9M to -$129K.
- What is the long-term trend for aTyr Pharma's financing cash flow?
- Over 4 years (2021 to 2025), aTyr Pharma's financing cash flow has grown at a -11.9% compound annual growth rate (CAGR), from $110.03M to $66.14M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about aTyr Pharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude